Rheumatology billing where the drug is the claim.
Rheumatology revenue depends on infusion and injectable drug claims: the drug line (J-code, units and NDC), the administration code, and the prior authorization behind both. Denials come from authorization gaps, unit or NDC mismatches, missing JW/JZ modifiers and administration codes that don't match the drug. We check every infusion claim against the order, the authorization and the payer's drug policy before it goes out.
Where rheumatology revenue slips.
Prior authorization for biologics
Infliximab, rituximab, abatacept, tocilizumab and similar drugs usually need prior authorization, often with step-therapy rules and re-authorization dates. An expired authorization turns a high-value claim into a denial.
Units, NDCs and wastage
J-codes are billed in units of a set dose (for example per 10 mg) with the NDC on the claim. Unit math errors, a missing NDC, or a missing JW/JZ modifier on single-dose vials can deny or short-pay the drug line.
Drugs paid below contract
Buy-and-bill practices pay for the drug up front. When a payer reimburses the drug below the contracted rate, it looks like a normal payment unless someone checks it line by line.
The lines that decide your reimbursement.
Infusion claims pair an administration code with a drug code. Both have to match the order, the authorization and the payer's policy.
Read more
| Code / modifier | What it covers | What goes wrong |
|---|---|---|
| 96365 / 96366 | IV infusion for therapy or prophylaxis: initial hour / each additional hour | Infusion time not documented; wrong code family for the payer's policy |
| 96413 / 96415 | Chemotherapy and complex biologic infusion: initial hour / each additional hour | Used for a drug the payer doesn't accept as complex; start and stop times missing |
| J1745 / J9312 / J0129 | Infliximab, 10 mg / rituximab, 10 mg / abatacept, 10 mg | Units don't match the dose given; NDC missing or mismatched |
| Modifiers JW / JZ | Drug amount discarded / no amount discarded (single-dose containers) | Missing on Medicare claims for single-dose vials, triggering edits |
| 20610 / 20611 | Major joint aspiration or injection without / with ultrasound guidance | Ultrasound billed without a recorded image and report |
| Modifier 25 | Separately identifiable E/M on the same day as an injection or infusion | E/M bundled because the note doesn't stand on its own |
Code descriptions are summarized. Always check the current CPT descriptor, NCCI edits and payer policy.
The four denial codes we see most in rheumatology.
Claim adjustment reason codes (CARCs) on the remittance tell you why a line wasn't paid. These four account for a large share of procedural denials.
| Code | What it means | How it shows up in rheumatology |
|---|---|---|
| CO-50 | Non-covered: not deemed medically necessary by the payer | Biologic given without meeting the payer's step-therapy criteria |
| CO-97 | Payment included in another service or procedure (bundled) | Hydration or IV push bundled with the infusion it ran alongside |
| CO-16 | Claim lacks information or has billing errors needed to process it | NDC missing, or units that don't match the NDC quantity |
| CO-4 | Procedure code inconsistent with the modifier, or a required modifier is missing | JW/JZ missing on single-dose drugs, or modifier 25 missing on a same-day E/M |
An infliximab drug line paid below the contracted drug rate.
The appeal attached the contract's drug fee schedule and the NDC-to-unit calculation for the dose given.
Illustrative example of how we build an appeal, not a specific client case. Results depend on the payer, contract and documentation.
Strategy backed by experienced specialists.
Strategy & Direct Client Partnership led by Rohit Pandey, backed by a dedicated team of credentialed medical coders (AAPC/AHIMA) and seasoned AR follow-up specialists.
How we work with your team
- We work inside your PM/EHR (eClinicalWorks, NextGen, AdvancedMD and others) under a HIPAA BAA.
- We act as a secondary recovery team on aging AR and complex appeals, alongside your staff.
- Weekly collection reporting to practice leadership.
- 6–7% of net collections; 10% of the IDR award only on No Surprises Act wins.
- A HIPAA BAA is signed before any PHI is shared.
Tell us about your rheumatology practice.
Share your claim volume and system. Book a 10-minute Meet, or skip the call and get a written summary by email.
Rheumatology billing questions
Which administration code should we bill for biologic infusions?
It depends on the drug and the payer. Medicare and many payers accept the chemotherapy and complex drug administration codes (96413–96417) for certain monoclonal antibodies and other biologic response modifiers, while others expect the therapeutic infusion codes (96365–96368). We follow each payer's written policy for each drug.
What are the JW and JZ modifiers?
For drugs from single-dose containers, Medicare requires the JW modifier on a separate line for any amount discarded, and the JZ modifier when nothing was discarded. Missing them can trigger edits or denials.
Can you help with biologic prior authorizations?
Yes. We track authorization and re-authorization dates and assemble the clinical documentation payers ask for, such as diagnosis, disease activity and prior therapies tried.
10 minutes. One screen. Your numbers.
A short Google Meet with Rohit to look at where your revenue stalls and whether contingency recovery makes sense for your practice. No software change, nothing to pay up front.